藥物釋放型支架市場報告：趨勢、預測和競爭分析（至 2031 年）

全球藥物釋放型支架市場前景看好，冠狀動脈疾病和周邊動脈疾病市場都存在機會。預計到 2031 年，全球藥物釋放型支架市場規模將達到 137 億美元，2025 年至 2031 年的複合年成長率為 6.3%。該市場的主要驅動力是全球老年人口的成長和心血管疾病發生率的上升。

• Lucintel 表示，根據塗層類型，聚合物基塗層由於其公認的有效性和適應性，將在預測期內繼續佔據較大的市場佔有率。
• 從應用角度來看，由於全球冠狀動脈疾病的盛行率不斷上升，冠狀動脈疾病預計將繼續成為主要領域。
• 從地區來看，北美預計在預測期內仍將是最大的地區，因為它擁有發達的醫療保健基礎設施和廣泛採用的先進醫療技術。

藥物釋放型支架市場的策略性成長機會

DES 市場受到關鍵應用領域中各種策略機會的推動。識別並利用這些機會可以幫助您擴大市場佔有率並改善患者的治療效果。

• 擴展到新興市場：由於心血管疾病盛行率上升和醫療保健投資增加，亞太地區和拉丁美洲等新興市場代表著巨大的成長機會。擴大市場影響將有助於推動收益成長並增加我們先進支架技術的使用機會。
• 下一代支架的開發：對具有改進的藥物輸送系統、更薄的支柱和生物分解性材料的下一代 DES 的投資具有巨大的成長潛力。這些創新解決了當前的局限性，並提高了支架治療的有效性和安全性，對臨床醫生和患者都具有吸引力。
• 數位健康技術的整合：將遠端監控和數據分析等數位健康技術納入 DES 治療通訊協定可以改善患者管理和治療結果。這些技術可以更好地追蹤支架性能和患者依從性，從而實現更有效的治療。
• 重視個人化醫療：對個​​人化醫療的日益重視為開發根據個別患者需求量身定做的 DES 解決方案創造了機會。利用基因和臨床數據，製造商可以創建最佳化的藥物配方和支架設計，以改善治療效果。
• 影像技術的進步：將 OCT 和血管內超音波等先進的成像技術融入 DES 可以提高支架放置和部署的準確性。這些進步使得我們能夠更好地評估血管狀況並更準確地確定支架尺寸，從而改善患者的治療效果。

DES 市場的策略成長機會由技術進步、市場擴張和個人化方法推動。相關人員可以利用這些機會來提高他們的市場地位並為改善患者照護做出貢獻。

藥物釋放型支架市場促進因素與挑戰

DES 市場受到影響其成長軌跡的各種促進因素​​和挑戰的影響。技術進步、經濟因素和監管問題在決定市場動態和影響相關人員的策略方面發揮關鍵作用。

推動藥物釋放型支架市場發展的因素包括：

• 技術進步：支架技術的創新，例如具有改進的藥物傳輸系統和生物分解性材料的下一代 DES，正在推動市場成長。這些進步將提高支架的有效性和安全性，從而改善患者的治療效果並提高採用率。
• 心血管疾病盛行率不斷上升：全球心血管疾病盛行率不斷上升是 DES 市場發展的主要驅動力。不斷增加的患者數量將對有效的治療方案產生巨大的需求，從而推動 DES 技術的發展。
• 監管支援和創新：簡化監管流程和對創新醫療設備的支援有助於加快新 DES 技術的核准和進入市場。這樣的法規環境鼓勵持續的研究和發展並促進市場擴張。
• 醫療保健支出的增加：醫療保健支出的增加和對先進醫療技術的投資正在促進 DES 市場的成長。增加心血管護理資金使得尖端支架技術得以採用。
• 更重視個人化醫療：強調個人化醫療和客製化治療方法正在推動 DES 的創新。根據個別患者情況量身訂做的支架設計和藥物治療方案可改善治療效果和市場需求。

藥物釋放型支架市場面臨的挑戰包括：

• 先進 DES高成本：先進 DES 技術高成本，可能限制其可近性和可負擔性，尤其是在新興市場。這項挑戰將影響市場滲透率和採用率，尤其是在成本敏感的地區。
• 監管和報銷障礙：複雜的監管要求和報銷問題可能會對市場進入和擴張構成挑戰。克服這些障礙需要大量的資源和專業知識，從而影響新 DES 技術的採用速度和簡易性。
• 競爭和市場飽和：DES 製造商和產品數量的增加可能會導致市場飽和和競爭加劇。面對日益激烈的競爭，企業很難實現產品差異化並維持市場佔有率。

技術進步和心血管疾病的增加等市場促進因素正在推動 DES 市場向前發展。然而，持續成長和市場發展需要應對高成本和監管障礙等挑戰。平衡這些因素對於塑造 DES 市場的未來至關重要。

目錄

第1章執行摘要

2. 全球藥物釋放型支架市場：市場動態

• 簡介、背景和分類
• 供應鏈
• 產業驅動力與挑戰

第3章市場趨勢與預測分析（2019-2031）

• 宏觀經濟趨勢（2019-2024）及預測（2025-2031）
• 全球藥物釋放型支架市場趨勢（2019-2024）及預測（2025-2031）
• 全球藥物釋放型支架市場（依塗層類型）
  • 聚合物基塗料
  • 無聚合物塗料
• 全球藥物釋放型支架市場（依應用）
  • 冠狀動脈疾病
  • 周邊動脈疾病

第4章區域市場趨勢與預測分析（2019-2031）

• 全球藥物釋放型支架市場（按區域）
• 北美藥物釋放型支架市場
• 歐洲藥物釋放型支架市場
• 亞太藥物釋放型支架市場
• 世界其他地區的藥物釋放型支架市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球藥物釋放型支架市場成長機會（依塗層類型）
  • 全球藥物釋放型支架市場的成長機會（按應用）
  • 全球藥物釋放型支架市場各區域成長機會
• 全球藥物釋放型支架市場的新趨勢
• 戰略分析
  • 新產品開發
  • 全球藥物釋放型支架市場的產能擴張
  • 全球藥物釋放型支架市場的企業合併
  • 認證和許可

第7章主要企業簡介

• Boston Scientific
• Medtronic
• Abbott Laboratories
• Biosensors
• Biotronik
• Lepu Medical Technology
• Terumo Medical
• Cook Medical
• Shandong JW Medical Systems
• B.Braun

The future of the global drug-eluting stent market looks promising, with opportunities in the coronary artery disease and peripheral artery disease markets. The global drug-eluting stent market is expected to reach an estimated $13.7 billion by 2031, with a CAGR of 6.3% from 2025 to 2031. The major drivers for this market are the increasing global elderly population and rising incidence of cardiovascular disorders.

• Lucintel forecasts that, within the coating type category market, polymer-based coatings will remain a larger segment over the forecast period due to their proven effectiveness and adaptability.
• Within the application category market, coronary artery disease will remain a larger segment due to the increasing global incidence of coronary artery disease.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of well-developed healthcare infrastructure and widespread adoption of advanced medical technologies in the region.

Gain valuable insights for your business decisions with our 150+ page report.

Emerging Trends in the Drug-Eluting Stent Market

Emerging trends in the DES market reflect advancements in technology, changing patient demographics, and evolving healthcare needs. These trends are influencing product development, market dynamics, and treatment outcomes, providing insights into the future of cardiovascular interventions.

• Biodegradable Stents: Biodegradable stents are gaining traction due to their ability to dissolve over time, reducing the risk of long-term complications and eliminating the need for permanent implants. These stents offer the advantage of restoring natural vessel function after degradation, which is beneficial for patients with complex cardiovascular conditions.
• Advanced Drug Delivery Systems: New DES technologies feature improved drug delivery systems that enhance the precision and efficacy of medication release. This includes the development of stents with controlled drug elution rates and novel drug combinations, which help reduce restenosis and improve overall treatment outcomes.
• Personalized Medicine: The trend toward personalized medicine in DES involves tailoring stent designs and drug formulations to individual patient profiles. Advances in genomics and diagnostics are allowing for more customized treatment approaches, potentially leading to better outcomes and reduced adverse events.
• Integration of Imaging Technologies: The integration of advanced imaging technologies, such as optical coherence tomography (OCT), is enhancing the precision of stent placement and deployment. These technologies provide detailed insights into vessel characteristics, allowing for more accurate stent sizing and placement.
• Regulatory Changes: Regulatory bodies are adopting more flexible and accelerated approval processes for innovative DES technologies. This includes streamlined pathways for clinical trials and faster market access, which encourage the development and availability of new stent options.

These emerging trends are reshaping the DES market by driving innovation, improving patient outcomes, and increasing market accessibility. As technology advances and regulatory landscapes evolve, the DES market will continue to grow and adapt to meet the needs of patients and healthcare providers.

Recent Developments in the Drug-Eluting Stent Market

Recent developments in the DES market are characterized by technological innovations, regulatory updates, and evolving healthcare needs. These changes are transforming the landscape of cardiovascular treatments, improving patient outcomes, and driving market growth.

• Introduction of Next-Generation Stents: Next-generation DES featuring thinner struts and improved drug coatings are now available. These advancements contribute to reduced restenosis rates and enhanced biocompatibility, leading to better long-term outcomes and patient satisfaction.
• Biodegradable Stent Technologies: The development of biodegradable stents, which gradually dissolve over time, has become a significant trend. These stents reduce the risk of chronic complications associated with permanent implants and restore natural vessel function, offering a promising alternative to traditional DES.
• Enhanced Drug Delivery Systems: Advances in drug delivery technologies, such as controlled-release mechanisms and novel drug formulations, are improving the efficacy of DES. These innovations ensure more precise and effective medication delivery, reducing the likelihood of restenosis and stent thrombosis.
• Increased Focus on Personalized Medicine: Personalized medicine is gaining traction, with DES being tailored to specific patient needs based on genetic and clinical profiles. This approach aims to optimize treatment outcomes by addressing individual variations in disease and response to therapy.
• Regulatory Changes and Market Access: Regulatory bodies are adopting more streamlined approval processes for innovative DES technologies. These changes facilitate quicker market entry for new stent designs and improve access to advanced treatment options for patients.

These recent developments are driving significant changes in the DES market, leading to improved patient outcomes and expanding market opportunities. As technology and regulations continue to evolve, the DES market is expected to grow and adapt to new challenges and opportunities.

Strategic Growth Opportunities for the Drug-Eluting Stent Market

The DES market is experiencing growth driven by various strategic opportunities in key applications. Identifying and leveraging these opportunities can lead to enhanced market presence and improved patient outcomes.

• Expansion into Emerging Markets: Emerging markets, such as Asia-Pacific and Latin America, present significant growth opportunities due to increasing cardiovascular disease prevalence and rising healthcare investments. Expanding market presence in these regions can drive revenue growth and increase access to advanced stent technologies.
• Development of Next-Generation Stents: Investment in next-generation DES with improved drug delivery systems, thinner struts, and biodegradable materials offers substantial growth potential. These innovations address current limitations and enhance the efficacy and safety of stent treatments, attracting both clinicians and patients.
• Integration of Digital Health Technologies: Incorporating digital health technologies, such as remote monitoring and data analytics, into DES treatment protocols can improve patient management and outcomes. These technologies enable better tracking of stent performance and patient compliance, leading to more effective treatments.
• Focus on Personalized Medicine: The growing emphasis on personalized medicine presents opportunities for developing customized DES solutions tailored to individual patient needs. By leveraging genetic and clinical data, manufacturers can create stents with optimized drug formulations and designs, enhancing treatment efficacy.
• Advancements in Imaging and Diagnostics: Integrating advanced imaging technologies, such as OCT and intravascular ultrasound, with DES can improve the precision of stent placement and deployment. These advancements allow for better assessment of vessel conditions and more accurate stent sizing, leading to improved patient outcomes.

Strategic growth opportunities in the DES market are driven by technological advancements, market expansion, and personalized approaches. By capitalizing on these opportunities, stakeholders can enhance their market position and contribute to improved patient care.

Drug-Eluting Stent Market Driver and Challenges

The DES market is shaped by a range of drivers and challenges that impact its growth trajectory. Technological advancements, economic factors, and regulatory issues play a crucial role in determining market dynamics and influencing stakeholder strategies.

The factors responsible for driving the drug-eluting stent market include:

• Technological Advancements: Innovations in stent technology, such as next-generation DES with improved drug delivery systems and biodegradable materials, are driving market growth. These advancements enhance the efficacy and safety of stents, leading to better patient outcomes and increased adoption.
• Growing Cardiovascular Disease Prevalence: The rising incidence of cardiovascular diseases globally is a significant driver for the DES market. Increasing patient numbers create a higher demand for effective treatment options, driving the growth of DES technologies.
• Regulatory Support and Innovation: Streamlined regulatory processes and support for innovative medical devices are facilitating faster approval and market entry for new DES technologies. This regulatory environment encourages ongoing research and development, driving market expansion.
• Rising Healthcare Expenditure: Increased healthcare spending and investment in advanced medical technologies are contributing to the growth of the DES market. Higher budgets for cardiovascular treatments enable the adoption of cutting-edge stent technologies.
• Growing Focus on Personalized Medicine: The emphasis on personalized medicine and tailored treatment approaches is driving innovation in DES. Customized stent designs and drug formulations based on individual patient profiles improve treatment outcomes and market demand.

Challenges in the drug-eluting stent market are:

• High Cost of Advanced DES: The high cost of advanced DES technologies can limit accessibility and affordability, particularly in emerging markets. This challenge affects market penetration and adoption rates, especially in cost-sensitive regions.
• Regulatory and Reimbursement Hurdles: Complex regulatory requirements and reimbursement issues can pose challenges for market entry and expansion. Navigating these hurdles requires significant resources and expertise, impacting the speed and ease of introducing new DES technologies.
• Competition and Market Saturation: The growing number of DES manufacturers and products can lead to market saturation and intensified competition. Differentiating products and maintaining market share amidst increasing competition can be challenging for companies.

Drivers such as technological advancements and growing cardiovascular disease prevalence are propelling the DES market forward. However, challenges like high costs and regulatory hurdles need to be addressed to ensure sustained growth and market development. Balancing these factors will be crucial for shaping the future of the DES market.

List of Drug-Eluting Stent Companies

Companies in the market compete based on product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies, drug-eluting stent companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the drug-eluting stent companies profiled in this report include-

• Boston Scientific
• Medtronic
• Abbott Laboratories
• Biosensors
• Biotronik
• Lepu Medical Technology
• Terumo Medical
• Cook Medical
• Shandong JW Medical Systems
• B.Braun

Drug-Eluting Stent by Segment

The study includes a forecast for the global drug-eluting stent market by coating type, application, and region.

Drug-Eluting Stent Market by Coating Type [Analysis by Value from 2019 to 2031]:

• Polymer-Based Coating
• Polymer-Free Coating

Drug-Eluting Stent Market by Application [Analysis by Value from 2019 to 2031]:

• Coronary Artery Disease
• Peripheral Artery Disease

Drug-Eluting Stent Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Drug-Eluting Stent Market

The drug-eluting stent (DES) market has experienced significant advancements in recent years, driven by technological innovations, regulatory changes, and evolving patient needs. These developments are reshaping market dynamics across various countries. This summary provides an overview of recent trends and advancements in the DES market in the United States, China, Germany, India, and Japan.

• United States: In the U.S., recent advancements include the introduction of next-generation DES with enhanced biocompatibility and thinner struts, which reduce restenosis rates and improve patient outcomes. The FDA's streamlined approval process for innovative stent technologies has accelerated market entry. Additionally, there is a growing emphasis on personalized medicine, with stent designs tailored to specific patient demographics and conditions.
• China: China's DES market has seen rapid growth due to increasing cardiovascular disease prevalence and advancements in medical technology. Local manufacturers are investing heavily in research and development to produce cost-effective DES, leading to a rise in domestic production. Regulatory reforms have also facilitated faster approval of new DES technologies, boosting market growth.
• Germany: Germany remains a leader in the DES market in Europe, driven by its strong healthcare infrastructure and emphasis on advanced medical technologies. Recent developments include the adoption of biodegradable stents and innovations in drug delivery systems, which enhance the long-term safety and efficacy of DES. The German market also benefits from a robust reimbursement framework that supports the adoption of cutting-edge stent technologies.
• India: In India, the DES market is expanding due to increasing cardiovascular disease incidence and rising healthcare expenditure. Local and international companies are introducing affordable DES solutions to cater to the growing patient base. The Indian government's initiatives to improve healthcare access and infrastructure are also contributing to the market's growth.
• Japan: Japan's DES market is characterized by high adoption rates of advanced stent technologies and a focus on improving patient outcomes through innovation. Recent developments include the introduction of ultra-thin strut stents and advanced drug formulations. Japan's stringent regulatory standards ensure that only high-quality DES are approved, maintaining a high standard for patient care.

Features of the Global Drug-Eluting Stent Market

Market Size Estimates: Drug-eluting stent market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Drug-eluting stent market size by coating type, application, and region in terms of value ($B).

Regional Analysis: Drug-eluting stent market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different coating types, applications, and regions for the drug-eluting stent market.

Strategic Analysis: This includes M&A, new product development, and the competitive landscape of the drug-eluting stent market.

Analysis of the competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers the following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the drug-eluting stent market by coating type (polymer-based coating and polymer-free coating), application (coronary artery disease and peripheral artery disease), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market, and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years, and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Drug-Eluting Stent Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Drug-Eluting Stent Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Drug-Eluting Stent Market by Coating Type
  • 3.3.1: Polymer-Based Coating
  • 3.3.2: Polymer-Free Coating
• 3.4: Global Drug-Eluting Stent Market by Application
  • 3.4.1: Coronary Artery Disease
  • 3.4.2: Peripheral Artery Disease

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Drug-Eluting Stent Market by Region
• 4.2: North American Drug-Eluting Stent Market
  • 4.2.1: North American Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.2.2: North American Market by Application: Coronary Artery Disease and Peripheral Artery Disease
• 4.3: European Drug-Eluting Stent Market
  • 4.3.1: European Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.3.2: European Market by Application: Coronary Artery Disease and Peripheral Artery Disease
• 4.4: APAC Drug-Eluting Stent Market
  • 4.4.1: APAC Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.4.2: APAC Market by Application: Coronary Artery Disease and Peripheral Artery Disease
• 4.5: ROW Drug-Eluting Stent Market
  • 4.5.1: ROW Market by Coating Type: Polymer-Based Coating and Polymer-Free Coating
  • 4.5.2: ROW Market by Application: Coronary Artery Disease and Peripheral Artery Disease

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Drug-Eluting Stent Market by Coating Type
  • 6.1.2: Growth Opportunities for the Global Drug-Eluting Stent Market by Application
  • 6.1.3: Growth Opportunities for the Global Drug-Eluting Stent Market by Region
• 6.2: Emerging Trends in the Global Drug-Eluting Stent Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Drug-Eluting Stent Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Drug-Eluting Stent Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Boston Scientific
• 7.2: Medtronic
• 7.3: Abbott Laboratories
• 7.4: Biosensors
• 7.5: Biotronik
• 7.6: Lepu Medical Technology
• 7.7: Terumo Medical
• 7.8: Cook Medical
• 7.9: Shandong JW Medical Systems
• 7.10: B.Braun